EuroPCR Roundup: Micell’s drug-eluting stent meets primary endpoint in non-inferiority study

Micell’s drug-eluting stent meets primary endpoint in non-inferiority study

Micell Technologies‘ sirolimus-eluting absorbable polymer coronary stent met the primary endpoint in the Dessolve III clinical trial, according to 12-month data published at EuroPCR. The stent demonstrated non-inferior safety and effectiveness outcomes compared to Xience‘s everolimus-eluting coronary stent system.

The 1,400-patient study evaluated the MiStent in patients with symptomatic coronary artery disease, including chronic stable angina, silent ischemia and acute coronary syndrome. All study participants qualified for percutaneous coronary interventions.

Get the full story at our sister site, Drug Delivery Business News.

The post EuroPCR Roundup: Micell’s drug-eluting stent meets primary endpoint in non-inferiority study appeared first on MassDevice.

from MassDevice http://ift.tt/2pGrArT